Local engineering of the lymph node environment to promote immune tolerance
US-2015374806-A1 · Dec 31, 2015 · US
Antibodies that bind amyloid oligomers
US9895429B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9895429-B2 |
| Application number | US-201514810760-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 28, 2015 |
| Priority date | Oct 15, 2010 |
| Publication date | Feb 20, 2018 |
| Grant date | Feb 20, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Embodiments of the invention are directed to compositions and methods related to immunogenic compositions comprising the amino acid sequence of SEQ ID NO:1 and amyloid oligomer specific antibodies that specifically bind an oligomer comprising such a peptide.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of detecting amyloid oligomers in a biological sample from a patient comprising (a) contacting the sample with an amyloid oligomer conformation specific antibody that specifically binds an oligomer of a peptide consisting of the amino acid sequence of SEQ ID NO:1, wherein the amyloid oligomer conformation specific antibody does not specifically bind a peptide monomer or fibril, forming a complex between the antibody and an amyloid oligomer in the sample; and (b) detecting the antibody and amyloid oligomer complex. 2. The method of claim 1 , wherein detecting the amyloid oligomers is by immunoassay. 3. The method claim 1 , wherein the biological sample comprises plasma, cerebrospinal fluid (CSF), brain tissue, neuronal tissue, or muscle tissue. 4. The method of claim 1 , wherein the amyloid oligomer conformation specific antibody comprises a detectable agent. 5. The method of claim 4 , wherein the detectable agent is a radioactive marker, a nucleic acid, a fluorescent label, or an enzymatic label. 6. A method for treating an amyloid related disease in a subject having or suspected of having an amyloid related disease comprising the step of administering to said subject an effective amount of an amyloid oligomer conformation specific antibody that specifically binds an oligomer of a peptide consisting of the amino acid sequence of SEQ ID NO: 1, wherein the amyloid oligomer conformation specific antibody does not specifically bind a peptide monomer or fibril. 7. The method of claim 6 , wherein 0.1 mg/kg to 500 mg/kg of the amyloid oligomer conformation specific antibody is administered to the subject. 8. The method of claim 6 , wherein the amyloid oligomer conformation specific antibody is administered into the blood or CSF.
Assignees
Inventors
Classifications
Emulsions, e.g. Freund's adjuvant, MF59 · CPC title
Neurological disorders, e.g. Alzheimer's disease · CPC title
comprising antibodies · CPC title
Prion diseases · CPC title
Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9895429B2 cover?
- Embodiments of the invention are directed to compositions and methods related to immunogenic compositions comprising the amino acid sequence of SEQ ID NO:1 and amyloid oligomer specific antibodies that specifically bind an oligomer comprising such a peptide.
- Who is the assignee on this patent?
- Kayed Rakez, Univ Texas
- What technology area does this patent fall under?
- Primary CPC classification A61K39/0007. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Feb 20 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).